Compounds > alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid

alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and dronabinol

alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid has been researched along with dronabinol in 2 studies

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Hoffman, AF; Kawamura, M; Laaris, N; Lupica, CR; Masino, SA1
Kokona, D; Thermos, K1

Other Studies

2 other study(ies) available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and dronabinol

ArticleYear
Control of cannabinoid CB1 receptor function on glutamate axon terminals by endogenous adenosine acting at A1 receptors.
    The Journal of neuroscience : the official journal of the Society for Neuroscience, 2010, Jan-13, Volume: 30, Issue:2

    Topics: Adenosine; alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Analysis of Variance; Animals; Benzoxazines; Biophysics; CA1 Region, Hippocampal; Caffeine; Calcium Channel Blockers; Dronabinol; Electric Stimulation; Excitatory Amino Acid Agonists; Excitatory Amino Acid Antagonists; Excitatory Postsynaptic Potentials; GABA Antagonists; Glutamic Acid; In Vitro Techniques; Methoxyhydroxyphenylglycol; Mice; Mice, Inbred C57BL; Mice, Knockout; Morpholines; Naphthalenes; Neural Inhibition; Neurons; Patch-Clamp Techniques; Phosphinic Acids; Picrotoxin; Piperidines; Presynaptic Terminals; Propanolamines; Pyrazoles; Quinoxalines; Receptor, Adenosine A1; Receptor, Cannabinoid, CB1; Xanthines

2010
Synthetic and endogenous cannabinoids protect retinal neurons from AMPA excitotoxicity in vivo, via activation of CB1 receptors: Involvement of PI3K/Akt and MEK/ERK signaling pathways.
    Experimental eye research, 2015, Volume: 136

    Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Amacrine Cells; Animals; Apoptosis; Arachidonic Acids; Cannabinoid Receptor Agonists; Choline O-Acetyltransferase; Dose-Response Relationship, Drug; Dronabinol; Endocannabinoids; Enzyme Inhibitors; Excitatory Amino Acid Agonists; Fluorescent Antibody Technique, Indirect; In Situ Nick-End Labeling; Intravitreal Injections; Male; MAP Kinase Signaling System; Neuroprotective Agents; Nitric Oxide Synthase Type I; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Polyunsaturated Alkamides; Proto-Oncogene Proteins c-akt; Rats; Rats, Sprague-Dawley; Receptor, Cannabinoid, CB1

2015